Comparison of Adjuvant regimens for cancer across tumor types #GU25. Nivolumab per Checkmate 274 for #bladdercancer rises to the top. https://t.co/d5owZb03ga...

KEYNOTE905: #Pembrolizumab + #EnfortumabVedotin before & after cystectomy improved EFS, OS & pCR vs surgery alone. A new SOC may be on the horizon for this high-risk group can’t wait to see the full data! #BladderCancer #Oncology #Immunotherapy #ADCake @MattGalsky @AndreaNecchi

Important to distinguish #serosal findings on #PSMA 🩻vs. #parenchymal Serosal lesions are better seen on #PSMA vs CT/MRI in #ProstateCancer but likely have an indolent course even with no 🚫therapy (even on the liver!) @melissaabel20 et al.@NatRevUrol https://t.co/UQ3gKEczvJ

Neoadjuvant Pembrolizumab and Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Nonurothelial Histologic Subtypes of Muscle-invasive #BladderCancer : A Phase 2 Trial https://t.co/z3yGdWYKvd This single-center phase 2 trial investigated neoadjuvant

Excited to share our new paper @EurUrolOncol! 🎉 We developed patient-centered, stage-specific FKSI-23 tools to better capture HRQOL in localized & metastatic RCC, moving beyond generic instruments to what truly matters to patients @tompowles1 @montypal https://t.co/2sTCZRdIjH

Exciting to see the trial I wrote at @ASCO @AACR #VailWorkshop2019 published. Thanks to mentor @PGrivasMDPhD and for the team @fredhutch carrying this through to completion! #PDG6

Evolving first-line and maintenance strategies in #UrothelialCancer: Insights from #ASCO25. Jacqueline Brown, MD @WinshipAtEmory sits down with @ERPlimackMD @FoxChaseCancer discussing the need for better biomarkers to identify which patients will benefit from specific approaches

🎙 New host @montypal of @cityofhope and @KimmieNgMD of @danafarber @DFarberYoungCRC discuss the alarming rise of early-onset GI cancers on the latest episode of the #ASCODailyNews Podcast: https://t.co/0rNjbKbpHN

Just 2 weeks to go! Curious how leading experts are applying MRD in real-world GU cancer care? Don’t miss this high-impact session at #WorldGU25 led by @maughanonc with @alantanmd, @ERPlimackMD, @MikeSchweizerMD, @Dr_RaviMadan, @brian_rini & Jeffrey Yorio, MD. Aug 21–23 |

PLEASE SHARE -> ICYMI, BCAN has created a fund of up to $1 million to help BC researchers whose federal funding has been interrupted. DEADLINE is 7/18. Click to learn more: https://t.co/m6wILXzjbE @MattGalsky @uretericbud @montypal @DRBakaloudiMD @m_e_nielsen @brian_rini

🎊 Abstract Submissions for #IKCSNA25 are Open! 🎊 Join the KCA on Nov 13-15 in Denver, CO for the 2025 IKCS: North America. Gather with top #kidneycancer experts to discuss and advance the field! But first! Submit your abstracts and register: https://t.co/BtpJZidr6L

👩‍⚕️ Are you a woman physician or researcher working in #kidneycancer? Our Women in RCC Virtual Coaching Program offers expert-led leadership training and peer support, guided by coach Sioux Thompson. 🗓️ Application deadline: Sept 1 🌐 Apply today: https://t.co/eVjLQqnuQb

🚨 Applications are OPEN! KCA is investing in the next generation of #KidneyCancer leaders through TWO unique mentorship opportunities: 🧡 KCA Mentorship Academy 🧡 Dr. Nizar Tannir Rare Kidney Cancer Scholar Program Apply now → https://t.co/8PssjopuLy

One month left to register for KCA's Women in RCC summer webinar! Join a conversation with @KimrynRathmell @OSUCCC_James - a leading voice in #kidneycancer research and care - about leadership and career development. 📆 August 14, 7-8 pm ET 👉 Sign up https://t.co/rCPWlwNfQM

EV-302 data: High CR rates and long-term survival with EV-pembro. @shilpaonc @ClevelandClinic joins @ERPlimackMD @FoxChaseCancer to discuss subset analysis data from EV-302, focusing on patients who achieved complete responses and partial responses with enfortumab vedotin +

Can ctDNA help us better define MRD in bladder cancer? Dr. @ERPlimackMD will explore this evolving space at #WorldGU25 in Nashville, TN. A critical topic, led by a true expert. Aug 21–23 | Up to 11.75 #CE credits Don’t wait—register today: https://t.co/uUPyclE655 #BladderCancer

@ERPlimackMD is joined by Andrea Necchi to discuss the SURE-02 trial, evaluating sacituzumab govitecan plus pembrolizumab in a bladder-sparing approach for muscle-invasive bladder cancer in this video with @UrologyToday:

🎉 We're so excited to have @KimrynRathmell @OSUCCC_James join us in conversation during the KCA's Women in RCC summer webinar next month! 👉Register today: https://t.co/rCPWlwNNGk

#ASCO25 Was humbled to see a patient approach me on the heels of our presentation yesterday & sharing his experience of achieving CR with EV-P & maintaining it despite on a break from EV for neuropathy. He thanked us for validating his personal experience & providing reassurance

Finally had a chance to listen to the discussion EVERYONE in the GU community is talking about via @ASCO Virtual Meeting. One of the most thoughtful & eloquent discussions I have ever seen by @jackiebrown_MD @WinshipAtEmory, summarizing excellent presentations from @MichvdHeijden

Deeply honored to step into the role of 2025-26 @ASCO President. My focus will be guided by the theme, "The Science and Practice of Translation: Improving Cancer Outcomes Worldwide." Looking forward to a productive & collaborative year ahead with our incredible ASCO community!